anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled remedy, easily applicable to affected parts, and capable of increasing the remedial effect without giving an irritation to the affected parts, by pulverizing a marsh snail under heating, and mixing the resultant powder with sulfur, and adding sesame oil thereto. CONSTITUTION:A marsh snail with the shell is heated and pulverized or pulverized and heated. The marsh snail is heated by the direct fire or in a roasting machine to such an extent as to remove completely the moisture or volatile substances in the living body. The pulverization is carried out by a suitable pulverizing means to give an almost coarse or fine powdery particulate powder. 100pts.wt. resultant roasted powder of the marsh snail is kneaded with 100- 200pts.wt. sulfur, and the resultant kneaded material is then mixed with 80- 10pts.wt., based on 100pts.wt. powder of the marsh snail, sesame oil, and further kneaded to give the aimed remedy for skin diseases. The resultant remedy is very effective for damages on the skin surface, e.g. scores after the skin burns, eczemas, scores of chilblains, etc.
The safety and effectiveness of NUCYNTA (tapentadol) tablets in pediatric patients ages 6 years and older who weigh at least 40 kg have been established. Use of NUCYNTA (tapentadol) tablets in pediatric patients ages 6 years and older who weigh at least 40 kg is based on one randomized, double-blind, placebo-controlled, multiple-dose efficacy and safety study of NUCYNTA (tapentadol) oral solution in 175 pediatric patients from birth to 17 years of age who had undergone surgery that would reliably produce moderate to severe pain and supported by pharmacokinetic and safety data from three open-label, single-dose studies of NUCYNTA (tapentadol) oral solution in 129 patients from birth to 17 years of age with moderate to severe acute pain from a surgical procedure [see Clinical Studies (14.2)].

The safety and effectiveness of NUCYNTA (tapentadol) tablets in pediatric patients less than 6 years of age have not been established. In pediatric patients less than 6 years of age, NUCYNTA (tapentadol) oral solution did not demonstrate efficacy compared to placebo when evaluated in one randomized, double-blind, placebo-controlled, multiple-dose study in 175 pediatric patients from birth to 17 years of age who had undergone surgery that would reliably produce moderate to severe pain [see Clinical Studies (14.2)]. 

The safety and effectiveness of NUCYNTA (tapentadol) tablets in pediatric patients who weigh less than 40 kg have not been established because the recommended dosage cannot be achieved with available tablet strengths. Consider use of another NUCYNTA product, such as NUCYNTA (tapentadol) oral solution, in patients who cannot swallow oral tablets or who weigh less than 40 kg [see Dosage and Administration (2.3)].

NUCYNTA (tapentadol) tablets have not been studied in pediatric patients with hepatic or renal impairment; therefore, use in these populations is not recommended [see Dosage and Administration (2.4)].
A smart bed system is disclosed herein. The smart bed system includes a smart bed adapted to accommodate a patient. The smart bed includes a smart bed computer operatively connectable to one or more monitoring devices. The smart bed computer is configured to store any monitored data recorded by the monitoring devices. The smart bed system also includes a server coupled with the smart bed computer. The server is configured to store any patient data pertaining to the patient. The server is configured to receive the monitored data from the smart bed computer and thereafter to store the monitored data as part of the patient data. The patient data can be selectively transferred from the server to the smart bed computer such that the patient data is accessible directly from the smart bed.
Multispectral photoacoustics enable non-invasive, inexpensive and dose-free real-time imaging of light-absorbing molecules (absorbers), e.g. Deoxyhemoglobin and oxygenated hemoglobin in human tissue. This allows blood oxygen saturation (sO2) to be determined at depths of up to several centimeters. Measurements of correlates to blood volume and collagen concentration are also made possible. In photoacoustic imaging, the tissue to be examined is irradiated with nanosecond short, near-infrared (650 - 1300nm) laser pulses. If laser light is locally absorbed by a tissue structure, it expands thermoelastically, which triggers an ultrasonic pressure wave, which is measured with the aid of an ultrasonic head. The initial pressure distribution and thus the absorption in the tissue can then be reconstructed. Since different molecules show distinct absorption behavior depending on the wavelength in the near infrared, by acquiring several wavelengths it is possible to estimate which absorbers are in which concentration in a tissue structure. The effectiveness and tolerability of modern high-precision radiation therapy for head and neck tumors largely depends on the quality of the imaging. The potential diagnostic benefits of photoacoustics in the radiotherapy of patients with head and neck tumors principally concern the target volume definition, the implementation of image-guided, adaptive radiotherapy and imaging tumor follow-up as well as the early detection of tumors.

Multispectral photoacoustics primarily enable the analysis of tumor hypoxia, which has been associated several times with increased radio resistance and an unfavorable prognosis. In addition, other factors, e.g. the blood volume and the collagen content in the tissue are analyzed.
PROBLEM TO BE SOLVED: To obtain a skin-cleansing agent excellent in skin aging preventing effect by including a plant of the family Betulaceae and a higher fatty acid soap. SOLUTION: This skin-cleansing agent comprises 0.001-10wt.% extract of a plant belonging to the genus platyphylla of the family Betulaceae and/or a plant belonging to the genus Alnus and 5-40wt.% 12-18C higher fatty acid soap (e.g. lauric acid). The plant extract is obtained by preferably using bark of the plant and extracting the bark with a solvent such as ethanol or water. The skin-cleansing agent can be prepared in the form of solid, paste, liquid, gel, foam, etc. Thereby, a skin-cleansing agent having promotion of proliferation and differentiation of epidermal cell, turn over promotion of horny layer, improving effect on keratin and skin-beautifying effect, etc., and excellent in prevention of skin aging is obtained.
The midline fascia was closed with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis. A Lightweight polypropylene mesh was used and placed on the anterior rectus fascia with an overlap of 3 cm. The mesh was fitted in the dissected space and it was fixed with PDS 2-0 suture. Fixing points are placed taking the mesh and the anterior fascia of the rectus muscle, at a distance of 3 cm between each point until completing its circunference.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.

The effect of Desonate on HPA axis function was investigated in pediatric subjects, 6 months to 6 years old, with atopic dermatitis covering at least 35% of their body, who were treated with Desonate twice daily for 4 weeks. One of 37 subjects (3%) displayed adrenal suppression after 4 weeks of use, based on the cosyntropin stimulation test. As follow-up evaluation of the subject's adrenal axis was not performed, it is unknown whether the suppression was reversible [see Use In Specific Populations (8.4) and Clinical Pharmacology (12.2)]. 

Pediatric patients may be more susceptible than adults to systemic toxicity from equivalent doses of Desonate due to their larger skin surface-to-body mass ratios [see Use In Specific Populations (8.4)].

Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure. 

An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. 

Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. 

Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.
The present invention relates generally to novel molecules capable of, inter alia, modulating apoptosis in mammalian cells and to genetic sequences encoding same. More particularly, the present invention relates to a novel member of the Bcl-2 family of proteins, referred to herein as "Bmf", and to genetic sequences encoding same and to regulatory sequences such as a promoter sequence directing expression of Bmf. Bmf comprises a BH3 domain which facilitates interaction to pro-survival Bcl-2 family members thereby triggering apoptosis. Bmf is regarded, therefore, as a BH3-only molecule. The molecules of the present invention are useful, for example, in therapy, diagnosis, antibody generation and as a screening tool for therapeutic agents capable of modulating physiological cell death or survival and/or modulating cell cycle entry. The present invention further contemplates genetically modified animals in which one or both alleles of Bmf are mutated or partially or wholly deleted alone or in combination with a mutation in one or both alleles of another Bcl-2-type molecule such as but not limited to Bim. The genetically modified animals are useful inter alia in screening for agents which ameliorate the symptoms of diseases caused by defects in apoptosis or which specifically promote apoptosis of target cells.
Mothers in Cohort 2 will receive a single dose of 900 mg of TDF combined with 600 mg emtricitabine, along with standard ZDV prophylaxis and/or other antiretrovirals prescribed by her physician. Infants will receive a single dose of TDF at 4 mg/kg combined with 3 mg/kg emtricitabine as soon as possible after delivery and within 6 hours of age as well as the standard 6 weeks of oral ZDV prophylaxis after birth.
PURPOSE: Provided is a composition for promoting hair-restoration which contains the ethanol or hot water extract of Allium tuberosum Roth. Therefore, the composition promotes the generation of hair roots and the metabolism of scalp to prevent depilation and promote hair-restoration. CONSTITUTION: The composition for hair-restoration is characterized by containing the extract of Allium tuberosum Roth as an active ingredient. The extract thereof is obtained by using hot water or ethanol as extracting solvent. The composition is formulated into concentrated extracts, sprays. drinks, granules, capsules, tablets or powder.
The invention discloses a medicinal wine for treating an asthmatic disease. The medicinal wine for treating the asthmatic disease is prepared from the following components in proportions: 20 to 30 grams of fructus forsythiae, 20 to 30 grams of radix scutellariae, 15 to 25 grams of fructus viticis negundo, 15 to 25 grams of fructus schisandrae, 15 to 25 grams of herba bidentis bipinnatae, 10 to 20 grams of radix achyranthis bidentatae, 10 to 20 grams of dry litchi chinensis, 10 to 20 grams of bulbus lilii, 5 to 15 grams of haloragis chinensis, 5 to 15 grams of herba houttuyniae and 1,000 milliliters of yellow wine. The medicinal wine for treating the asthmatic disease is obtained through coarsely crushing the fructus forsythiae, the radix scutellariae, the fructus viticis negundo, the fructus schisandrae, the herba bidentis bipinnatae, the radix achyranthis bidentatae, the dry litchi chinensis, the bulbus lilii, the haloragis chinensis and the herba houttuyniae, then loading the coarsely crushed components in a cloth bag, putting the cloth bag in a sealed container, adding the yellow wine into the sealed container for soaking the coarsely crushed components, and sealing the sealed container for 30 days or above. In the components of the medicinal wine provided by the invention, the fructus forsythiae and the radix scutellariae are in charge of being antibacterial and antiphlogistic, the fructus viticis negundo, the fructus schisandrae and the herba bidentis bipinnatae are in charge of regulating the flow of qi and benefiting qi, the radix achyranthis bidentatae, the dry litchi chinensis and the bulbus lilii are in charge of promoting blood circulation and strengthening the spleen, the haloragis chinensis and the herba houttuyniae are in charge of eliminating sputum and relieving asthma, and the yellow wine is used as an assistant medicament. The medicinal wine for treating the asthmatic disease is used for treating the asthmatic disease; the pathological mechanism is hit; both symptoms and root causes are treated. The medicinal wine for treating the asthmatic disease is accurate and simple in compatibility, is wide in medicinal sources, is simple and convenient to make, and is low in cost.
The invention relates to the technical field of Chinese patent medicaments, in particular to an oral liquid for treating verruca vulgaris and a preparation method thereof. The oral liquid comprises the following raw materials in part by weight: 2 to 6 parts of coke, 1 to 3 parts of ginger and 0.5 to 2 parts of water. The coke has the effects of raising spirit and quenching thirst; the ginger has the effects of dispelling cold, removing smelling, accelerating blood circulation, warming stomach and the like and has preventive effect on various diseases of human bodies; and the water plays a role in regulating liquor concentration. The raw materials of the oral liquid are common materials easily obtained in life, so the oral liquid has low cost; and a dietotherapy method is used, so the oral liquid is convenient to use, has no pain, untoward effect or skin harm to the human bodies and has no toxic or side effects. The oral liquid can make the verruca vulgaris incrusted and dropped in a short time to achieve the effects of radical cure and no recrudescency. Repeated clinical tests verify that the oral liquid has radical cure rate of 99.28 percent for people of all ages and both sexes, and the verruca vulgaris cannot recur.
This study will test the efficacy of split-dose R-CHOP for the treatment of elderly patients with de novo diagnosis of DLBCL or transformed DLBCL. Split-dose R-CHOP involves giving Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy at 14 days' interval with Rituximab given once/month. The safety for every 14-day CHOP administration was studied in a large prospective randomized control trial of patients up to the age of 80 years. In this study, R-CHOP given every 14 days for up to 6 cycles was felt to be the best method of delivery of chemotherapy. Receiving greater than 6 cycles of R-CHOP chemotherapy was not found to be beneficial compared to participants receiving 6 cycles of R-CHOP. Additionally, an interim response adapted approach by combining imaging and MRD testing will be used to identify participants who will receive an abbreviated chemotherapy course if they are both Positron Emission Tomography/Computed Tomography (PET/CT) and Minimum Residual Dose (MRD) negative.

In the proposed study, participants will receive a 50% dose reduction of CHOP chemotherapy on Day 1 and Day 15 of each cycle with full dose Rituximab on Day 1 for up to a total of 6 months of chemotherapy. Participants who are MRD and PET/CT negative after 2 months will be placed on an abbreviated regimen with R-CHOP x 4 additional doses with full dose Rituximab and a 50% dose reduction in CHOP chemotherapy. The hypothesis is that this method of administration of R-CHOP will be a safe and effective form of chemotherapy for older patients with DLBCL and will allow older patients to receive curative intent treatment.
The intervention group patients were given their electronic drug monitoring feedback data at each monthly visit. The study coordinator would quickly calculate whether the patient's adherence was below 95% in the previous month. If so, that patient was flagged for enhanced counseling with a clinic doctor and this counseling was based on a printout containing the electronic drug monitoring data.
The number of deaths due to AIDS in high-risk populations continues to increase. Nationwide approximately 25 percent of AIDS patients are intravenous (IV) drug abusers, and it is very likely that an increasingly larger number of AIDS patients receiving AZT therapy will have had a history of IV drug abuse. The major chemical treatment for IV drug abuse is daily methadone maintenance therapy, and IV drug abusers who are HIV positive represent a large number of patients who will undergo long-term treatment with both methadone and AZT. Therefore, the study of potential drug interactions is essential.

The 18 patients are patients with AIDS or ARC. Nine are control patients who are not receiving methadone and are not IV drug abusers. Nine are former IV drug abusers who have been maintained on methadone for at least 6 months and who have been receiving a constant daily dose of methadone for at least 1 month. Plasma and urine levels of methadone are determined over a 4 hour period. The dose of AZT: For the pharmacokinetic study of AZT, plasma and urine samples are taken after oral dose of AZT and an intravenous dose of AZT in the control and methadone groups.
The invention provides a rodenticide for resisting the breeding of the female lasiopodomys brandtii, which adopts sophoricoside as the active ingredient, belonging to the technical field of biological prevention and treatment. The lasiopodomys brandtii mainly inhabits on the meadow with vegetation degradation, the population is strong in fertility, the quantitive variation amplitude each year and each season is great, the breeding is rapid, the collapsing force for the steppe vegetation is strong, therefore, the lasiopodomys brandtii is a formidable enemy for the animal husbandry, and is one of the main rat damages in the Inner Mongolia steppe, and the rat damage severely damages the ecological environment, and also threatens the human health. For a long time, people adopt many methods to control the population quantity of the lasiopodomys brandtii, wherein the method for controlling the population quantity of the injurious rats by adopting the antifertility technology is a novel technology developed in recent years. The invention relates to the female sterile rodenticide prepared by taking sophoricoside as the active ingredient, which is used for controlling the breeding of the lasiopodomys brandtii. Compared with the traditional ecological deratting method and chemical poison bait method, the antifertility technology has the advantages of long acting time, obvious control effect, small toxic and side effects caused to the environment, and the like, and can more effectively inhibit the over-compensatory effect of the population of the injurious rats. If the novel technology is applied to the agriculture-forestry-stockbreeding production, the population quantity of the injurious rats can be effectively controlled, and thus the broad economic benefit is obtained.
<FORM:0886969/IV (a)/1> <FORM:0886969/IV (a)/2> <FORM:0886969/IV (a)/3> <FORM:0886969/IV (a)/4> In a process for making fibres or films of mineral or organic material, at least one stream of melted material is brought into contact with at least one distributing device which divides and projects the material to distribute it over a number of surfaces which rotate about a common axis surrounding the distributing device, the material being guided by the surfaces to be distributed substantially homogeneously over the whole periphery of the surfaces, so that each surface projects the material evenly in the form of fibres or films.  As shown in Figs. 1, 1a, molten glass 5 falls into a cylindrical distributing member 2, joined by members 2a to a rotatable supporting frame 4 having integral horizontally extending plates 1, the glass being projected through apertures 3 in the wall of the cylinder 2 to form thin layers on the surfaces of the plates 1.  Additional plates can be arranged between the plates 1 to guide the glass on to the plates 1, which may have a narrower section adjacent the apertures 3.  The plates 1 may have smooth edges for forming films or radial lines, channels or teeth to assist in the formation of fibres.  For attenuating the fabrics, an annular combustion chamber surrounds the frame 4 and has a slot 11 through which flames or hot gases act on the peripheries of the plates 1. Burners 12 with deflectors 13 may also be used to heat the rotating body.  The edges 1a of the plates 1 may be inclined, as in Fig. 6, or straight, and their diameters may be the same or may increase towards the lowest.  In another embodiment, partly shown in Fig. 8b, two plates 14, 15 are joined by curved blades 18 which, as shown, have waves, but which may be formed with projecting rings or may be smooth.  In this embodiment, outside the combustion chamber a blowing chamber is provided for carrying away the fibres.  In place of the rotating distributing chamber 2, a fixed or movable pneumatic distributing device may be used.
In vitro method for the diagnosis of atherosclerosis which comprises measuring the level of ALDH4A1 or the level of antibodies anti-ALDH4A1 in a sample obtained from the subject, wherein a significantly higher level of ALDH4A1 or of antibodies anti-ALDH4A1 which respect to the level measured in healthy control subjects, is indicative that the patient is suffering from atherosclerosis. In vitro use of ALDH4A1 or an antibody anti-ALDH4A1 for the diagnosis of atherosclerosis. Antibody or antibody fragment specifically binding to ALDH4A1 for use in a method for in vivo imaging of atherosclerosis lesions in a patient or for in vivo diagnosis of atherosclerosis. Kit. Antibody or antibody fragment specifically binding to ALDH4A1 for use in the treatment of atherosclerosis. Pharmaceutical composition comprising an antibody or antibody fragment specifically binding to ALDH4A1 and pharmaceutically acceptable excipients or carriers.